Sep. 8 at 11:46 AM
$ABVX Eli Lilly structures a final definitive agreement utilizing a CVR, a highly probable life-sciences layout would look like this:ComponentTarget Pricing / StructureStrategic JustificationUpfront Base Consideration
$85.00 -
$95.00 / share (Cash or Stock)Provides immediate liquidity to ABVX holders close to its traditional baseline valuation before the speculative premium.CVR Catalyst 1: Regulatory Milestone+
$15.00 / share contingent on FDA ApprovalTriggers only if the FDA officially approves obefazimod for Ulcerative Colitis by a firm deadline (e.g., Q4 2027).CVR Catalyst 2: Clinical Expansion+
$10.00 / share contingent on Phase 3 dataTriggers if the upcoming mid-2027 Phase 2b data for Crohn's disease successfully hits its primary endpoints and advances into a Phase 3 trial.CVR Catalyst 3: Commercial Sales Tier+
$15.00 / share contingent on net salesTriggers only if the drug reaches
$1B in global annual net sales within 3 years post-commercialization.
